As a result, in the era of modern systemic therapy with adjuvant chemotherapy typically containing anthracycline and taxanes, higher proportion of HER2-positive patients receiving anti-HER2 therapy, and standard adjuvant hormonal therapy in HR-positive patients, the risk of tumor recurrence has been significantly decreased. Here, ERBB2 is linked to neoplasm.